David L Legro, MD | |
333 Borthwick Ave, Portsmouth, NH 03801-7128 | |
(603) 433-5106 | |
(603) 433-5180 |
Full Name | David L Legro |
---|---|
Gender | Male |
Speciality | Internal Medicine |
Experience | 25 Years |
Location | 333 Borthwick Ave, Portsmouth, New Hampshire |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1861579302 | NPI | - | NPPES |
30206826 | Medicaid | NH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208M00000X | Hospitalist | 11922 (New Hampshire) | Secondary |
208M00000X | Hospitalist | 016064 (Maine) | Secondary |
207R00000X | Internal Medicine | 11922 (New Hampshire) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Northern Light Mercy Hospital | Portland, ME | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mercy Hospital | 6103737812 | 207 |
News Archive
Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.
U.S. Census Bureau data shows a rise in the number of Americans lacking health insurance. 47 million people did not have health coverage in 2006, up from 44.8 million in 2005.
Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful "silencing" of a widely recognized cancer gene via RNA interference (RNAi) in humans.
Levels of health disparity have increased substantially for people born in the United States after 1980, according to new research.
› Verified 6 days ago
Entity Name | Mercy Hospital |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629078712 PECOS PAC ID: 6103737812 Enrollment ID: O20040217000943 |
News Archive
Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.
U.S. Census Bureau data shows a rise in the number of Americans lacking health insurance. 47 million people did not have health coverage in 2006, up from 44.8 million in 2005.
Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful "silencing" of a widely recognized cancer gene via RNA interference (RNAi) in humans.
Levels of health disparity have increased substantially for people born in the United States after 1980, according to new research.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
David L Legro, MD 333 Borthwick Ave, Portsmouth, NH 03801-7128 Ph: (603) 433-5106 | David L Legro, MD 333 Borthwick Ave, Portsmouth, NH 03801-7128 Ph: (603) 433-5106 |
News Archive
Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.
U.S. Census Bureau data shows a rise in the number of Americans lacking health insurance. 47 million people did not have health coverage in 2006, up from 44.8 million in 2005.
Arrowhead Research Corporation today announced that the clinical trial being conducted by majority-owned subsidiary, Calando Pharmaceuticals, Inc., has demonstrated systemic delivery of siRNA and the successful "silencing" of a widely recognized cancer gene via RNA interference (RNAi) in humans.
Levels of health disparity have increased substantially for people born in the United States after 1980, according to new research.
› Verified 6 days ago
Robert Millstein, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 100 Campus Dr, Suite 12, Portsmouth, NH 03801 Phone: 603-422-8208 Fax: 603-422-8219 | |
Mr. Hanad Omar, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Avenue, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Thomas P Clairmont Jr., MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 330 Borthwick Ave, Suite 205, Portsmouth, NH 03801 Phone: 603-436-6115 Fax: 603-433-5567 | |
Daniel L Davies, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 155 Borthwick Ave, Suite 202w, Portsmouth, NH 03801 Phone: 603-433-8434 Fax: 603-436-6608 | |
Brian Choi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 215-442-5031 | |
Dr. Sucharit Suresh Joshi, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 875 Greenland Rd, #c-10, Portsmouth, NH 03801 Phone: 603-436-3433 Fax: 603-427-5115 | |
Dr. Michael Casimir Danielski, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 875 Greenland Rd, #c-10, Portsmouth, NH 03801 Phone: 603-436-3433 Fax: 603-427-5115 |